NTA: Applications in drug delivery

April 8, 2016

It is well established that the use of nanotechnology in medicine and more specifically drug delivery is spreading rapidly. Driven by the diminishing rate of discovery of new biologically active compounds that can be exploited therapeutically to treat disease and with fewer new drugs entering the market every year, interest in the use of nanoparticle’s versatile and multifunctional structures for the delivery of existing drugs has grown rapidly. Nanoparticles offer better pharmacokinetic properties, controlled and sustained release, and targeting of specific cells, tissues or organs such (e.g. in new ways in which to cross the blood-brain barrier). All these features can improve the efficacy of existing drugs (Malam et al., 2011). Nanoparticles in this context have been defined as colloidal systems of submicron size that can be constructed from a large variety of materials in a large variety of compositions. Commonly defined nanoparticle vectors include: liposomes, micelles, dendrimers, solid lipid nanoparticles, metallic nanoparticles, semiconductor nanoparticles and polymeric nanoparticles. Therefore, nanoparticles have been extensively employed to deliver drugs, genes, vaccines and diagnostics into specific cells/tissues (Ram et al., 2011).

Spotlight

Pii (Pharmaceutics International, Inc.)

Pii (Pharmaceutics International, Inc) is a multinational contract formulation development, Clinical Trial Materials (CTM), and commercial manufacturing company with corporate headquarters in Hunt Valley, Maryland, USA. Founded in 1994, Pii manufactures a wide range of dosage forms covering solid, semi-solid and aseptic filling. This service is complemented by full analytical and regulatory support.

OTHER WHITEPAPERS
news image

Pharma R And D Review

whitePaper | February 11, 2021

Welcome to Pharmaprojects’ 2021 review of trends in pharmaceutical R&D. For almost 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article I’ll examine the state of play at the start of 2021.

Read More
news image

Manufacturing High-Quality Capsule Products for Pharmaceutical and Nutraceutical Applications

whitePaper | October 25, 2022

To confirm the suitability of empty hard capsules for use in the application of quality-by-design (QbD) in the development and manufacturing of finished pharmaceutical products, the quality target product profile (QTPP) defined by eight critical quality attributes (CQA’s) was examined.

Read More
news image

BUILDING RESILIENT SUPPLY CHAINS REVITALIZING AMERICAN MANUFACTURING AND FOSTERING BROAD-BASED GROWTH

whitePaper | February 24, 2022

The COVID-19 pandemic and resulting economic dislocation revealed long-standing vulnerabilities in our supply chains. The pandemic’s drastic impacts on demand patterns for a range of medical products including essential medicines wreaked havoc on the U.S. healthcare system.

Read More
news image

Determine the right dust collection equipment for tablet press applications

whitePaper | October 13, 2022

Though tablet compression does not generate large volumes of fugitive dust, safe and efficient collection of whatever dust is created by this process is critical. The dust collector linked to the press can contribute to reliable, consistent performance

Read More
news image

MEETING CURRENT AND FUTURE SERIALISATIONCHALLENGES

whitePaper | December 5, 2022

Serialisation has emerged as a complex challenge for the pharmaceuticals sector which is facing a multiplicity of differing regulations that vary from one country to another.

Read More
news image

How Specialty Pharmacy Can Drive Better Outcomes in Diabetes

whitePaper | July 21, 2022

The growing costs of the diabetes epidemic in the U.S. are staggering. Over 37 million Americans around 11% of the population now have diabetes, and according to a recent study, over 60 million Americans are expected to have the disease by 2060.

Read More

Spotlight

Pii (Pharmaceutics International, Inc.)

Pii (Pharmaceutics International, Inc) is a multinational contract formulation development, Clinical Trial Materials (CTM), and commercial manufacturing company with corporate headquarters in Hunt Valley, Maryland, USA. Founded in 1994, Pii manufactures a wide range of dosage forms covering solid, semi-solid and aseptic filling. This service is complemented by full analytical and regulatory support.

Events